PL1638551T3 - Związki i kompozycje immunosupresyjne - Google Patents

Związki i kompozycje immunosupresyjne

Info

Publication number
PL1638551T3
PL1638551T3 PL04752678T PL04752678T PL1638551T3 PL 1638551 T3 PL1638551 T3 PL 1638551T3 PL 04752678 T PL04752678 T PL 04752678T PL 04752678 T PL04752678 T PL 04752678T PL 1638551 T3 PL1638551 T3 PL 1638551T3
Authority
PL
Poland
Prior art keywords
compositions
immunosuppressant
immunosuppressant compounds
diseases
prevention
Prior art date
Application number
PL04752678T
Other languages
English (en)
Inventor
Thomas H Marsilje
Nathanael S Gray
Tao Jiang
Wenshuo Lu
Shifeng Pan
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of PL1638551T3 publication Critical patent/PL1638551T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL04752678T 2003-05-19 2004-05-19 Związki i kompozycje immunosupresyjne PL1638551T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47193103P 2003-05-19 2003-05-19
PCT/US2004/015701 WO2004103309A2 (en) 2003-05-19 2004-05-19 Immunosuppressant compounds and compositions
EP04752678A EP1638551B1 (en) 2003-05-19 2004-05-19 Immunosuppressant compounds and compositions

Publications (1)

Publication Number Publication Date
PL1638551T3 true PL1638551T3 (pl) 2012-05-31

Family

ID=33476902

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04752678T PL1638551T3 (pl) 2003-05-19 2004-05-19 Związki i kompozycje immunosupresyjne

Country Status (17)

Country Link
US (2) US7060697B2 (pl)
EP (1) EP1638551B1 (pl)
JP (1) JP4575920B2 (pl)
CN (4) CN1816544B (pl)
AT (1) ATE537825T1 (pl)
AU (2) AU2004240649A1 (pl)
BR (1) BRPI0410454A (pl)
CA (1) CA2524054C (pl)
CY (1) CY1112505T1 (pl)
DK (1) DK1638551T3 (pl)
ES (1) ES2379169T3 (pl)
MX (1) MXPA05012459A (pl)
PL (1) PL1638551T3 (pl)
PT (1) PT1638551E (pl)
SI (1) SI1638551T1 (pl)
WO (1) WO2004103309A2 (pl)
ZA (1) ZA200508203B (pl)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241790B2 (en) * 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
KR20110140139A (ko) * 2003-08-29 2011-12-30 오노 야꾸힝 고교 가부시키가이샤 Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
US7638637B2 (en) * 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
TW200538433A (en) * 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
US7718704B2 (en) * 2004-02-24 2010-05-18 Irm Llc Immunosuppressant compounds and compositions
US7781617B2 (en) 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
WO2006063033A2 (en) * 2004-12-06 2006-06-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
BRPI0519012A2 (pt) * 2004-12-13 2008-12-23 Ono Pharmaceutical Co derivado do Ácido aminocarboxÍlico e seu uso medicinal
CA2595960A1 (en) * 2005-02-08 2006-08-17 Novartis Ag Antilymphocyte antibody induction by combination of an s1p receptor agonist/modulator and of immunosuppressive drugs
US7754703B2 (en) * 2005-02-14 2010-07-13 University Of Virginia Patent Foundation Cycloalkane-containing sphingosine 1-phosphate agonists
WO2006115188A1 (ja) * 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited ヘテロ環化合物
BRPI0615133A2 (pt) * 2005-08-23 2011-05-03 Irm Llc compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso
PL1932522T3 (pl) * 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
JP2009528274A (ja) * 2006-01-27 2009-08-06 ユニバーシティ オブ バージニア パテント ファンデーション 神経因性疼痛の治療法
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JP2009526073A (ja) * 2006-02-09 2009-07-16 ユニバーシティ オブ バージニア パテント ファンデーション 二環式スフィンゴシン−１−リン酸受容体アナログ
JP5140593B2 (ja) 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
CA2659598A1 (en) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and s1p receptor modulator having same as an active ingredient
CA2669104A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
AU2007323557A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
JP2010510249A (ja) * 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−燐酸アゴニスト活性を有するテトラリンアナログ
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP2011503046A (ja) * 2007-11-08 2011-01-27 ファイザー・インク シクロブチルカルボン酸誘導体
GB0725101D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725104D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
WO2009131090A1 (ja) * 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
GB0807910D0 (en) * 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
EP2695615A3 (en) * 2008-07-23 2014-04-30 Novartis AG Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
HRP20160890T1 (hr) 2008-08-27 2016-09-23 Arena Pharmaceuticals, Inc. Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja
TWI392673B (zh) 2008-08-27 2013-04-11 Calcimedica Inc 調控細胞內鈣離子濃度之化合物
WO2010043000A1 (en) * 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators and their use thereof
JP2012512884A (ja) * 2008-12-18 2012-06-07 ノバルティス アーゲー １−（４−｛１−［（ｅ）−４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ］−エチル｝−２−エチル−ベンジル）−アゼチジン−３−カルボン酸の新規の多形相
US8741923B2 (en) * 2008-12-18 2014-06-03 Merck Serono Sa Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
KR20110101159A (ko) * 2008-12-18 2011-09-15 노파르티스 아게 신규 염
CN102574822A (zh) 2009-08-04 2012-07-11 阿米拉制药公司 作为溶血磷脂酸受体拮抗剂的化合物
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
MX2012006028A (es) * 2009-11-24 2012-06-19 Allergan Inc Compuestos novedosos como moduladores de receptor con utilidad terapeutica.
UY33178A (es) * 2010-01-13 2011-08-31 Sanofi Aventis Derivados de ácido carboxílico heteroxíclicos que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido
TWI478929B (zh) * 2010-01-13 2015-04-01 Sanofi Aventis 含２，５，７－經取代唑并嘧啶環之羧酸衍生物
PT2523962E (pt) * 2010-01-14 2014-02-06 Sanofi Sa Derivados de ácidos carboxílicos com um anel oxazolopirimidina substituído em 2,5
MX2012007837A (es) * 2010-01-14 2012-07-30 Sanofi Sa Derivados de oxazolopirimidina 2, 5 - sustituidos.
JP5841068B2 (ja) * 2010-01-14 2016-01-06 サノフイ ２，５−置換されたオキサゾロピリミジン環を有する複素環式カルボン酸誘導体
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
ES2548683T3 (es) 2010-04-23 2015-10-20 Bristol-Myers Squibb Company Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
EP2609095A4 (en) 2010-08-27 2014-06-18 Calcimedica Inc COMPOUNDS MODULATING INTRACELLULAR CALCIUM
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
AU2011336968A1 (en) * 2010-12-03 2013-07-11 Allergan, Inc. Novel oxime azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators
WO2012074926A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
DK2648726T3 (da) 2010-12-07 2018-07-16 Amira Pharmaceuticals Inc Polycyklisk lpa1-antagonist og anvendelser deraf
KR20130126659A (ko) 2010-12-07 2013-11-20 아미라 파마슈티칼스 인코포레이티드 리소포스파티드산 수용체 길항제 및 섬유증 치료에서의 그의 용도
EA034451B1 (ru) * 2011-02-07 2020-02-10 Байоджен Ма Инк. Модуляторы s1p
WO2012138797A1 (en) 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
RU2013150173A (ru) * 2011-04-14 2015-05-20 Аллерган, Инк. Метиламинные производные бициклического фенила как модуляторы рецепторов сфингозин-1-фосфата
US8735402B2 (en) * 2011-07-07 2014-05-27 Sanofi Cycloalkyloxycarboxylic acid derivatives
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
CA2862375A1 (en) * 2012-02-03 2013-08-08 Novartis Ag Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
DK2767532T3 (en) 2012-12-21 2016-09-12 Nat Inst For Quantum And Radiological Science And Tech New connection for reproduction of tau protein heavy in the brain.
US8957061B2 (en) 2013-02-13 2015-02-17 Allergan, Inc. Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators
WO2014175287A1 (ja) 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
CN103408501B (zh) * 2013-08-14 2016-03-09 合肥医工医药有限公司 苄基嘧啶衍生物、其制备方法及其医药用途
US9714240B2 (en) 2013-09-17 2017-07-25 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
EP3046909A4 (en) 2013-09-17 2017-03-29 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
EP3049405A4 (en) 2013-09-26 2017-03-08 Pharmakea Inc. Autotaxin inhibitor compounds
EP3071561B1 (en) 2013-11-22 2021-03-24 Sabre Therapeutics LLC Autotaxin inhibitor compounds
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
JP6564029B2 (ja) 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
AU2016229268B2 (en) 2015-03-06 2020-09-10 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
CA2986759C (en) 2015-05-27 2025-06-17 Sabre Therapeutics Llc AUTOTAXIN INHIBITORS AND THEIR USES
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
DK3331876T3 (da) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma
JP2018525429A (ja) * 2015-08-28 2018-09-06 アッヴィ・インコーポレイテッド Ｓ１ｐ調節剤としての縮合複素環化合物
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
WO2017214575A1 (en) * 2016-06-10 2017-12-14 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CA3036064A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
WO2018048942A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Uses of a lysyl oxidase-like 2 inhibitor
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MX2019009843A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
CN115650976A (zh) 2017-07-24 2023-01-31 生命医药有限责任公司 RORγ的抑制剂
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
TW201946624A (zh) 2018-05-09 2019-12-16 新旭生技股份有限公司 雜芳基化合物及其用途
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN110776450B (zh) * 2018-07-27 2022-09-27 广东东阳光药业有限公司 一种辛波莫德晶型及其制备方法
CN112955431A (zh) 2018-09-06 2021-06-11 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
WO2020114475A1 (zh) * 2018-12-06 2020-06-11 上海济煜医药科技有限公司 作为免疫调节的芳环衍生物及其制备方法和应用
WO2020114477A1 (zh) * 2018-12-06 2020-06-11 上海济煜医药科技有限公司 作为免疫调节剂的化合物及其制备方法和应用
CN111484434A (zh) * 2019-01-29 2020-08-04 东莞市东阳光仿制药研发有限公司 一种辛波莫德晶型及其制备方法
WO2020173346A1 (zh) * 2019-02-25 2020-09-03 广东东阳光药业有限公司 一种辛波莫德的制备方法
CN114728071B (zh) 2019-11-13 2024-12-06 新旭生技股份有限公司 用于降解tau蛋白聚集体的化合物及其用途
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN119776509A (zh) * 2023-10-08 2025-04-08 华东师范大学 Ndufa10基因和S1pr4基因突变在肌病诊断、预测和治疗中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH540247A (de) 1967-04-21 1973-09-28 Ciba Geigy Ag Verfahren zur Herstellung von heterocyclischen, Asthylendoppelbindungen enthaltenden Verbindungen
IL109161A0 (en) * 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
AU3325295A (en) * 1994-08-24 1996-03-14 Eli Lilly And Company Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists
US6110922A (en) * 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
EP1424078A4 (en) * 2001-09-04 2009-03-25 Ono Pharmaceutical Co RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT
WO2003037271A2 (en) * 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
WO2003051837A2 (de) * 2001-12-14 2003-06-26 Zentaris Gmbh Tetrahydrocarbazolderivate als liganden für g-protein gekoppelte rezeptoren (gpcr)
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
JP4430941B2 (ja) * 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
DE10207844A1 (de) * 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
DK1501804T3 (da) * 2002-04-26 2009-10-12 Hoffmann La Roche Isoquinolinderivat MAO-B-inhibitorer
JP2007186422A (ja) * 2004-01-28 2007-07-26 Astellas Pharma Inc アリールスルフィド誘導体

Also Published As

Publication number Publication date
DK1638551T3 (da) 2012-04-02
CN1791395A (zh) 2006-06-21
ES2379169T3 (es) 2012-04-23
CN1791592B (zh) 2012-07-04
CN1787817A (zh) 2006-06-14
CN1791395B (zh) 2012-09-26
EP1638551A2 (en) 2006-03-29
CY1112505T1 (el) 2015-12-09
JP2006528987A (ja) 2006-12-28
ZA200508203B (en) 2007-02-28
MXPA05012459A (es) 2006-02-22
CN1816544B (zh) 2011-06-08
WO2004103309A2 (en) 2004-12-02
ATE537825T1 (de) 2012-01-15
US7060697B2 (en) 2006-06-13
JP4575920B2 (ja) 2010-11-04
CN1787817B (zh) 2011-09-07
EP1638551B1 (en) 2011-12-21
BRPI0410454A (pt) 2006-06-13
CA2524054C (en) 2012-04-24
US7462629B2 (en) 2008-12-09
AU2004240649A1 (en) 2004-12-02
WO2004103309A3 (en) 2005-03-03
HK1090559A1 (en) 2006-12-29
US20050014724A1 (en) 2005-01-20
CA2524054A1 (en) 2004-12-02
EP1638551A4 (en) 2008-12-31
CN1791592A (zh) 2006-06-21
US20050009786A1 (en) 2005-01-13
SI1638551T1 (sl) 2012-04-30
AU2008203088A1 (en) 2008-08-07
PT1638551E (pt) 2012-03-28
CN1816544A (zh) 2006-08-09

Similar Documents

Publication Publication Date Title
TW200505442A (en) Immunosuppressant compounds and compositions
TW200505428A (en) Immunosuppressant compounds and compositions
EP1638551A4 (en) IMMUNOSUPPRESSIVE COMPOUNDS AND COMPOSITIONS
WO2004113330A8 (en) Immunosuppressant compounds and compositions
WO2005082089A3 (en) Immunosuppressant compounds and compositions
WO2004071442A3 (en) Novel bicyclic compounds and compositions
TW200612892A (en) Novel compounds
TW200505837A (en) Novel compounds
TW200519075A (en) Novel compounds
IL190654A (en) Methods of Methyl-Sulfonamido-Propanamido, Processes for Preparation and Medicines Containing Them
TW200531689A (en) Therapeutic agents
GB0313612D0 (en) Organic compounds
TW200504034A (en) Therapeutic agents
TW200635903A (en) Therapeutic agents
TW200716120A (en) Pyrazolo-pyrimidine derivatives as mGluR2 antagonists
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
TW200514781A (en) Novel compounds
GB0420831D0 (en) Novel compounds
TW200633986A (en) Therapeutic agents
TW200716566A (en) Prokineticin 2 receptor antagonists
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
TW200517382A (en) Imidazole derivatives
TW200734324A (en) Therapeutic agents
TW200801005A (en) Acetylenic piperazines as metabotropic glutamate receptor antagonists
MX2007010841A (es) 8-pirrolidinobenzimidazoles biciclicos sustituidos, un metodo para su produccion y su uso como medicamentos.